Tyrosine supplements for ADHD symptoms with comorbid phenylketonuria

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 21, Issue 2, 2009, Pages 228-230

  Posner, Jonathan ^a   Gorman, Daniel ^b   Nagel, Bonnie J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TYROSINE;

ATTENTION DEFICIT DISORDER; CASE REPORT; CHILD; COMORBIDITY; DISEASE EXACERBATION; DRUG TOLERABILITY; FRUSTRATION; HUMAN; IMPULSIVENESS; LETTER; MALE; PHENYLKETONURIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 67749101975     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2009.21.2.228     Document Type: Letter

References (4)

1. Wappner R, Cho S, Kronmal RA, et al: Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors. Pediatrics 1999; 104: e68
2. Poustie VJ, Rutherford P: Tyrosine supplementation for phenylketonuria. Cochrane Database Syst Rev 2000; CD001507
3. Barkley RA: Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997; 121:65-94
4. Volkow ND, Wang GJ, Fowler JS, et al: Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/ hyperactivity disorder. Biol Psychiatry 2005; 57:1410-2145